ORCHARD THERAPEUTICS PLC's ticker is ORTX and the CUSIP is 68570P101. A total of 83 filers reported holding ORCHARD THERAPEUTICS PLC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $3,117,026 | -25.8% | 8,401,687 | 0.0% | 0.01% | -25.0% |
| Q3 2022 | $4,201,000 | -13.4% | 8,401,687 | +1.1% | 0.01% | -7.7% |
| Q2 2022 | $4,853,000 | -18.0% | 8,309,859 | 0.0% | 0.01% | 0.0% |
| Q1 2022 | $5,917,000 | -46.1% | 8,309,859 | 0.0% | 0.01% | -35.0% |
| Q4 2021 | $10,969,000 | -19.7% | 8,309,859 | +40.0% | 0.02% | -23.1% |
| Q3 2021 | $13,655,000 | +16.6% | 5,936,914 | +122.5% | 0.03% | +18.2% |
| Q2 2021 | $11,712,000 | -39.5% | 2,667,800 | 0.0% | 0.02% | -42.1% |
| Q1 2021 | $19,368,000 | +68.1% | 2,667,800 | 0.0% | 0.04% | +58.3% |
| Q4 2020 | $11,525,000 | +12.2% | 2,667,800 | +6.7% | 0.02% | 0.0% |
| Q3 2020 | $10,275,000 | -36.1% | 2,500,000 | -6.8% | 0.02% | -40.0% |
| Q2 2020 | $16,089,000 | -5.0% | 2,681,502 | +19.2% | 0.04% | -20.0% |
| Q1 2020 | $16,943,000 | -45.2% | 2,250,000 | 0.0% | 0.05% | -27.5% |
| Q4 2019 | $30,938,000 | +148.0% | 2,250,000 | +114.3% | 0.07% | +122.6% |
| Q3 2019 | $12,474,000 | – | 1,050,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 4,081,972 | $9,388,000 | 2.74% |
| RA Capital Management | 11,028,722 | $25,366,000 | 0.35% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 6,949,416 | $15,984,000 | 0.31% |
| Avidity Partners Management LP | 3,836,798 | $8,825,000 | 0.20% |
| Casdin Capital, LLC | 2,575,000 | $5,923,000 | 0.15% |
| Vivo Capital, LLC | 1,325,736 | $3,049,000 | 0.14% |
| Artal Group S.A. | 1,803,858 | $4,149,000 | 0.09% |
| Eversept Partners, LP | 569,581 | $1,310,036 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 374,811 | $862,000 | 0.09% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,078,315 | $2,480,000 | 0.07% |